Acibuca, AynurSezer, AhmetYilmaz, MustafaSumbul, Ahmet TanerDemircan, SenolMuderrisoglu, Ibrahim HaldunOzyilkan, Ozgur2022-06-232022-06-2320210300-0605https://journals.sagepub.com/doi/pdf/10.1177/03000605211053755http://hdl.handle.net/11727/7122Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods A retrospective review of our center's medical records was performed, including female patients aged >= 18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%. Results Data from 41 female patients with a mean age of 52 +/- 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.enginfo:eu-repo/semantics/openAccessBreast cancercardiotoxicitytrastuzumab emtansineleft ventricular ejection fractionechocardiogrammetastatic breast cancerarticle4912180007305973000012-s2.0-85121351478